TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D in Pregnancy and Lactation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women between 18-42 years of age~* within 18 plus/minus 3 weeks gestation~* planning to breastfeed their infant~* a singleton pregnancy~Exclusion Criteria:~* Any co-morbid condition such pre-gestational diabetes, TB, cardiac or renal disease, HIV/AIDS, chronic hypertension, inflammatory bowel disease, autoimmune disease, liver disease, or epilepsy; conditions associated with vitamin D malabsorption: celiac disease, gastric bypass;~* History of previous adverse pregnancy outcome \[preterm delivery \<37; weeks GA, stillbirth, severe pre-eclampsia, eclampsia, HELLP syndrome (hemolytic anemia, elevated liver enzymes, and low platelet count)\];~* Women will also be ineligible if they are taking more than 10 µg day supplemental vitamin D or drugs known to interfere with vitamin D metabolism (i.e corticosteroids).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of the Reia Vaginal Pessary

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females with Stage II pelvic organ prolapse or greater~* Users of a Gellhorn or ring style pessary, inclusive of sizes 1.5-3, for \>3 months' duration~* Capable of giving informed consent~Exclusion Criteria:~* Pregnancy Short vaginal length (total vaginal length \< 8 cm), or subjective vaginal narrowing~* Deep vaginal erosion noted with removal of current pessary~* Presence of vesicovaginal fistula~* Presence of rectovaginal fistula~* Vaginal, rectal, or bladder tumor~* Presence of open wound or tear near vagina or anus by exam prior to removal of current pessary~* Untreated vaginal or urinary infection requiring treatment~* History of recurrent urinary tract or vaginal infections~* Inflammatory bowel disease~* Chronic pain syndromes of pelvic or anorectal origin~* Previous pelvic floor surgery in last 12 months~* Congenital malformation of bladder, rectum, or vagina~* Significant medical condition interfering with study participation (psychologic, neurologic, active drug/alcohol abuse, etc.)~* Planning pregnancy in next 6 months~* Previous treatment failure with a pessary

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reia Vaginal Pessary (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Chronic hepatitis C, diagnosed by positive anti-hepatitis C virus(HCV) antibodies and detected HCV ribonucleic acid(RNA) at screening in addition to:~  1. positive anti-HCV antibodies or detected HCV RNA at least 6 months prior to screening; or,~ 2. liver biopsy consistent with chronic HCV infection.~* HCV infection of genotype 1 confirmed by genotypic testing at screening~* Therapy-naïve to interferon, pegylated interferon, ribavirin or any antiviral / immunomodulatory drug for acute or chronic HCV infection.~* Plasma HCV RNA = 100,000 IU/mL at screening~Exclusion criteria:~* Hepatitis C infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening~* Human immunodeficiency virus (HIV) co-infection~* Decompensated liver disease, or history of decompensated liver disease~* Body weight \< 40 or \> 125 kg at screening~* Hemoglobin \<12.0g/dL for women and \<13.0g/dL for men at screening~* White blood cell count \<3000 cells/mm3 at screening~* Absolute neutrophil count \< 1,500 cells/mm3 at screening~* Platelet count \< 90,000 /mm3 at screening~* Serum creatinine \> 1.5xUpper Limit of Normal range(ULN) or creatinine clearance =50 mL/min at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI 207127 NA, BI 201335 NA(high dose), R (Type: EXPERIMENTAL): Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
- BI 207127 NA,BI 201335 NA(low dose),RBV (Type: EXPERIMENTAL): Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~1. Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation~2. Age 18 years or older~3. Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater than 95 mmHg at randomisation~4. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigators discretion)~Exclusion criteria Mean in-clinic seated cuff SBP \>/= 200 mmHg and/or Diastolic Blood Pressure \[DBP\] \>/= 95 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- telmisartan and amlodipine (Type: EXPERIMENTAL): telmisartan and amlodipine used in combination vs amlodipine or telmisartan
- amlodipine (Type: ACTIVE_COMPARATOR): telmisartan and amlodipine used in combination vs amlodipine or telmisartan
- telmisartan (Type: ACTIVE_COMPARATOR): telmisartan and amlodipine used in combination vs amlodipine or telmisartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* If female, must be either postmenopausal or surgically sterile~* A Body Mass Index (BMI) ≥18 kg/m\^2 to ≤40 kg/m\^2, inclusive.~* A diagnosis of T2DM~* Drug naïve or is being treated with no more than 2 oral antihyperglycemic agents (thiazolidenediones are excluded)~* Judged to be in good health except for T2DM~* Willing to follow a standard weight maintaining diet throughout the study~* A nonsmoker or has not used nicotine or nicotine-containing products for at least 3 months~Exclusion Criteria:~* A history of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* A history of myositis or complaints including diffuse myalgias, muscle tenderness, or weakness.~* A history of cancer (malignancy) excepting adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix~* Has clinically unstable diabetic retinopathy, neuropathy, and/or clinical evidence of gastroparesis (frequent nausea, bloating or vomiting, severe gastroesophageal reflux, early satiety)~* A history of type 1 diabetes mellitus and/or history of ketoacidosis~* Taking a medication for a co-morbid condition that is not permitted during the study~* A history of significant multiple and/or severe allergies~* Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus~* Had major surgery, donated or lost 1 unit of blood within 4 weeks prior to study participation~* Participated in another investigational trial within 4 weeks prior to study participation~* Consumes excessive amounts of alcoholic or caffeine-containing beverages~* A regular user of illicit drugs or a history of drug or alcohol abuse within the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-8666 50 mg (Type: EXPERIMENTAL): MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
- MK-8666 150 mg (Type: EXPERIMENTAL): MK-8666, 150 mg, oral, QD, for Days 1 to 14
- MK-8666 500 mg (Type: EXPERIMENTAL): MK-8666, 500 mg, oral, QD for Days 1 to 14
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral, QD for Days 1 to 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Risk Screening and Risk Reduction in Women Vets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* For Patient Activities: Women VA patients with any cardiovascular risk factors~* For Key Stakeholder Activities: VA staff affiliated with the Women's Health Clinic~Exclusion Criteria:~* For Patient Activities: Men \& Patients with cognitive impairment precluding informed consent~* For Key Stakeholder Activities: non- VA staff

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: OTHER): The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Spinal Cord Injured~* Between the ages of 18-65 years old.~* Level of injury is between C1-T12~* Primarily wheelchair dependent for ambulation~* Have a spinal cord injury that is ASIA Impairment Scale (AIS) grade of A, B or C~* Injury occurred more than 1 year ago~* Low blood pressure (Systolic BP less than 110 mmHg for males, Systolic BP less than 100 mmHg for females)~* Primary language is English~* I am right handed~Exclusion Criteria:~* Currently have an illness or infection~* Severe history of AD (more than 3 symptomatic events per week, evidence of blood pressure elevations above 140/90 mmHg,significant adverse subjective symptoms reporting)~* Hypertension or diabetes~* History of Traumatic Brain Injury (TBI)~* Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.)~* History of epilepsy or other seizure disorder~* Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder~* Within the past 6 months, abused illicit drugs~* Pre-screen mini mental status exam score of less than 24, as rated by the researcher~* Vision is impaired- more than 20/60 in worst eye (with prescription eyewear)~* Coronary heart and/or artery disease~* Major surgery in the last 30 days~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Midodrine (Type: EXPERIMENTAL): Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
- Placebo (Type: PLACEBO_COMPARATOR): Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have type 2 diabetes mellitus for at least 1 year.~2. Are at least 18 years old.~3. Have been receiving oral antihyperglycemic medications (OAMs), without insulin, for at least 3 months immediately prior to the study and have been on stable doses of at least 2 of the following OAMs for the 6 weeks prior to Visit 1, at or above the doses defined in the following: Metformin--1500 milligrams per day (mg/day); Sulfonylureas--1/2 the maximum daily dose, according to the local package insert; Dipeptidyl peptidase-intravenous (DPP-IV) inhibitors-- 1/2 the maximum daily dose, according to the local package insert; Thiazolidinediones (TZDs)--30 mg/day pioglitazone or 4 mg/day rosiglitazone.~4. Have a hemoglobin A1c (HbA1c) greater than or equal to 7.5% and less than or equal to 10.0%, as measured by a central laboratory before Visit 2.~5. Body mass index (BMI) greater than or equal to 25 and less than or equal to 45 kilograms per square meter (kg/m2).~Exclusion Criteria~1. Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks.~2. Have taken any glucose-lowering medications not included in Inclusion Criterion \[3\] (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide) in the past 3 months before Visit 1.~3. Have had more than 1 episode of severe hypoglycemia, within 6 months prior to entry into the study, or is currently diagnosed as having hypoglycemia unawareness.~4. Have a history of renal transplantation or are currently receiving renal dialysis or creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL) (177 micromoles per liter \[micromol/L\]).~5. Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease (alanine transaminase \[ALT\], or aspartate transaminase \[AST\] greater than 2 times the upper limit of the reference range, as defined by the local laboratory) or have albumin value above or below the normal reference range, as defined by the local laboratory.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Lispro Protamine Suspension (Type: EXPERIMENTAL): Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
- Detemir (Type: ACTIVE_COMPARATOR): Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or older~* Gastric cancer, locally advanced or metastatic~* No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6 months~* One measurable lesion~* ECOG \< 3~* Biology and biochemistry within normal limits~* Life expectancy \> 12 weeks~Exclusion Criteria:~* Other palliative chemotherapy for this cancer~* Other cancer in the last 5 years~* Previous treatment with irinotecan~* Atropine treatment not possible~* Concomitant cancer therapy except bone radiotherapy~* Metastases to brain or meninges with symptoms~* Other severe pathology uncontrolled~* Problem of compliance

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Irinotecan associated to fluorouracil and leucovorin (Type: EXPERIMENTAL): On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DAS181 for Severe COVID-19: Compassionate Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens~2. Hypoxemic~3. Severe COVID-19~4. If female, subject must not be pregnant or nursing.~5. Non-vasectomized males are required to practice effective birth control methods~6. Capable of understanding and complying with procedures as outlined in the protocol as judged by the Investigator and able to sign informed consent form prior to the initiation of any screening or study-specific procedures.~Exclusion Criteria:~1. ALT or AST\> 8 x ULN~2. (ALT or AST\> 3 x ULN) and (Total bilirubin\> 2.5 x ULN or INR\> 2.0 x ULN)~3. Female subjects who have a positive pregnancy test and are breastfeeding~4. Subjects using any other investigational antiviral drugs during the hospitalization before enrollment.~5. Subjects participating in other clinical trials~6. Subjects may be transferred to a non-participating hospital within 72 hours~7. People who cannot cooperate well due to mental illness, have no self-control, and cannot express clearly~8. Severe underlying diseases affecting survival~9. Critical COVID-19 requiring mechanical ventilator at the time enrolled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DAS181 Treatment (Type: EXPERIMENTAL): Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High-dose chemotherapy followed by peripheral autologous stem cell transplantation~* Underlying disease: Hodgkin Disease, non-Hodgkin-lymphoma, multiple myeloma or solid tumor~Exclusion Criteria:~* Allogenic stem cell transplantation~* Aplastic anemia~* Antibiotic treatment within seven days prior to randomization~* Signs and symptoms of current infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): moxifloxacin 400 mg tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): identical appearing placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Versus Levetiracetam In Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (male or female) must be \> 18 years of age, with a diagnosis of epilepsy with partial seizures, as defined in the International League Against Epilepsy (ILAE) classification of seizures.~* Partial seizures may be simple or complex, with or without secondary tonic-clonic generalization.~* Subjects must be have been diagnosed with epilepsy for at least 2 years, and must have been unresponsive to treatment with at least two but no more than five prior antiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosages of 1 or 2 standard AEDs.~Exclusion Criteria:~* Females who are pregnant, breastfeeding, or intend to become pregnant during the course of the trial will be excluded~* Subjects with other neurologic illness that could impair endpoint assessment, or subjects with Lennox-Gastaut syndrome, absence seizures, status epileptics within the 12 months prior to trial entry, or with seizures due to an underlying medical illness or metabolic syndrome, will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): None
- A (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete